Jovana Klajic

  • Post Doc; PhD
 

Publications 2024

Fjermeros K, Ghannoum S, Geisler SB, Bhargava S, Tahiri A, Klajic J, Lüders T, Fongård M, Nawaz MS, Bosnjak-Olsen T, Buvarp UE, Rosenskiold AKJ, Nguyen NT, Sletbak TT, Seyedzadeh M, Selsås K, Porojnicu AC, Skjerven HK, Hovda T, Sahlberg KK, Torland LA, Lyngra M, Hammarström CL, Hönigsperger EB, Noone JC et al. (2024)
The NEOLETRIB trial: neoadjuvant treatment with Letrozole and Ribociclib in ER-positive, HER2-negative breast cancer
Future Oncol, 20 (32), 2457-2466
DOI 10.1080/14796694.2024.2377531, PubMed 39073142

Publications 2019

Vaclavikova R, Klajic J, Brynychova V, Elsnerova K, Alnaes GIG, Tost J, Kristensen VN, Rob L, Kodet R, Skapa P, Mrhalova M, Soucek P (2019)
Development of high‑resolution melting analysis for ABCB1 promoter methylation: Clinical consequences in breast and ovarian carcinoma
Oncol Rep, 42 (2), 763-774
DOI 10.3892/or.2019.7186, PubMed 31173253

Publications 2017

Fleischer T, Klajic J, Aure MR, Louhimo R, Pladsen AV, Ottestad L, Touleimat N, Laakso M, Halvorsen AR, Grenaker Alnæs GI, Riis ML, Helland Å, Hautaniemi S, Lønning PE, Naume B, Børresen-Dale AL, Tost J, Kristensen VN (2017)
DNA methylation signature (SAM40) identifies subgroups of the Luminal A breast cancer samples with distinct survival
Oncotarget, 8 (1), 1074-1082
DOI 10.18632/oncotarget.13718, PubMed 27911866

Publications 2016

Eftang LL, Klajic J, Kristensen VN, Tost J, Esbensen QY, Blom GP, Bukholm IR, Bukholm G (2016)
GFRA3 promoter methylation may be associated with decreased postoperative survival in gastric cancer
BMC Cancer, 16, 225
DOI 10.1186/s12885-016-2247-8, PubMed 26984265

Publications 2014

Fleischer T, Frigessi A, Johnson KC, Edvardsen H, Touleimat N, Klajic J, Riis ML, Haakensen VD, Wärnberg F, Naume B, Helland A, Børresen-Dale AL, Tost J, Christensen BC, Kristensen VN (2014)
Genome-wide DNA methylation profiles in progression to in situ and invasive carcinoma of the breast with impact on gene transcription and prognosis
Genome Biol, 15 (8), 435
DOI 10.1186/PREACCEPT-2333349012841587, PubMed 25146004

Klajic J, Busato F, Edvardsen H, Touleimat N, Fleischer T, Bukholm I, Børresen-Dale AL, Lønning PE, Tost J, Kristensen VN (2014)
DNA methylation status of key cell-cycle regulators such as CDKNA2/p16 and CCNA1 correlates with treatment response to doxorubicin and 5-fluorouracil in locally advanced breast tumors
Clin Cancer Res, 20 (24), 6357-66
DOI 10.1158/1078-0432.CCR-14-0297, PubMed 25294903

Publications 2013

Klajic J, Fleischer T, Dejeux E, Edvardsen H, Warnberg F, Bukholm I, Lønning PE, Solvang H, Børresen-Dale AL, Tost J, Kristensen VN (2013)
Quantitative DNA methylation analyses reveal stage dependent DNA methylation and association to clinico-pathological factors in breast tumors
BMC Cancer, 13, 456
DOI 10.1186/1471-2407-13-456, PubMed 24093668

Publications 2012

Ree AH, Kristensen AT, Saelen MG, de Wijn R, Edvardsen H, Jovanovic J, Abrahamsen TW, Dueland S, Flatmark K (2012)
Tumor phosphatidylinositol-3-kinase signaling and development of metastatic disease in locally advanced rectal cancer
PLoS One, 7 (11), e50806
DOI 10.1371/journal.pone.0050806, PubMed 23226389

Publications 2010

Jovanovic J, Rønneberg JA, Tost J, Kristensen V (2010)
The epigenetics of breast cancer
Mol Oncol, 4 (3), 242-54
DOI 10.1016/j.molonc.2010.04.002, PubMed 20627830

Muggerud AA, Rønneberg JA, Wärnberg F, Botling J, Busato F, Jovanovic J, Solvang H, Bukholm I, Børresen-Dale AL, Kristensen VN, Sørlie T, Tost J (2010)
Frequent aberrant DNA methylation of ABCB1, FOXC1, PPP2R2B and PTEN in ductal carcinoma in situ and early invasive breast cancer
Breast Cancer Res, 12 (1), R3
DOI 10.1186/bcr2466, PubMed 20056007